WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved JANUMET ® XR ...

Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are not adequately controlled on metformin or sitagliptin alone or in patients already being treated with ...

PRINCETON, N.J. & LONDON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY), and AstraZeneca (NYSE: AZN) today announced that KOMBIGLYZE ™ XR (saxagliptin and metformin HCl extended-release), ...

PRINCETON, N.J. & LONDON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) approved KOMBIGLYZE ™ ...

May 21, 2009 — The US Food and Drug Administration (FDA) has approved pioglitazone HCl and metformin HCl extended-release tablets for the adjunctive treatment of type 2 diabetes mellitus, amlodipine ...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved a label update for FARXIGA ® (dapagliflozin) and XIGDUO ® XR (dapagliflozin ...

AstraZeneca announced that the Food and Drug Administration (FDA) has approved Xigduo XR (dapagliflozin and metformin HCl extended-release) for adjunct treatment to diet and exercise to improve ...

Dapagliflozin, metformin HCl ext-rel; 2.5mg/1000mg, 5mg/500mg, 5mg/1000mg, 10mg/500mg, 10mg/1000mg; tabs. Xigduo® XR (dapagliflozin and metformin HCl extended-release) tablets have markings on one ...

The US Food and Drug Administration (FDA) has approved a once-daily combination of dapagliflozin and metformin hydrochloride extended-release (Xigduo XR, AstraZeneca) for the treatment of adults with ...

The Drugs Controller General of India (DCGI) has informed the drug controllers of states and Union Territories that the antidiabetic fixed dose combination (FDC) of voglibose 0.2 mg and metformin Hcl ...